Aligos Therapeutics (ALGS) FCF Margin (2021 - 2025)
Historic FCF Margin for Aligos Therapeutics (ALGS) over the last 5 years, with Q3 2025 value amounting to 3285.43%.
- Aligos Therapeutics' FCF Margin fell 16773500.0% to 3285.43% in Q3 2025 from the same period last year, while for Sep 2025 it was 3017.96%, marking a year-over-year decrease of 13227400.0%. This contributed to the annual value of 2239.63% for FY2024, which is 13934500.0% down from last year.
- Per Aligos Therapeutics' latest filing, its FCF Margin stood at 3285.43% for Q3 2025, which was down 16773500.0% from 1606.63% recorded in Q2 2025.
- In the past 5 years, Aligos Therapeutics' FCF Margin registered a high of 317.09% during Q2 2023, and its lowest value of 10304.09% during Q4 2021.
- In the last 5 years, Aligos Therapeutics' FCF Margin had a median value of 1606.63% in 2025 and averaged 2305.04%.
- As far as peak fluctuations go, Aligos Therapeutics' FCF Margin surged by 98270200bps in 2022, and later crashed by -34456300bps in 2025.
- Over the past 5 years, Aligos Therapeutics' FCF Margin (Quarter) stood at 10304.09% in 2021, then soared by 95bps to 477.07% in 2022, then crashed by -136bps to 1127.82% in 2023, then crashed by -169bps to 3036.8% in 2024, then decreased by -8bps to 3285.43% in 2025.
- Its FCF Margin was 3285.43% in Q3 2025, compared to 1606.63% in Q2 2025 and 6723.15% in Q1 2025.